---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033839"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:12:08.385189+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%

## Summary
- Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).
- Net loss Q4 2025 $9.0M vs $9.2M prior year; FY net loss $38.8M vs $37.8M.
- Closed $70M credit facility from Perceptive Advisors; $60M drawn at closing, $10M option by Apr 2027.
- Promoted Howard Langstein, MD, FACS to Chief Medical Officer effective March 1, 2026.
- FY 2026 revenue guidance: at least 8% growth; Q1 2026 revenue expected ~$18.5M.

## SEC filing metadata
- accession: 0001104659-26-033839
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/0001104659-26-033839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/tm269387d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033839
- JSON: https://secwatch.observer/filing/0001104659-26-033839.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033839.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.
  - Period: the fourth quarter of 2025 and the fiscal year ended December 31, 2025
  - Result: reported results
  source text: On March 24, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/0001104659-26-033839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.